Global NMDA specialist
Company Details
Company Introduction
Working together for therapeutic options for managing clients with a major depressive disorder (MDD), It is estimated that up to 18% of patients diagnosed with a major depressive disorder (MDD) do not respond to conventional treatments and medications and so these are classified as treatment resistant. Our knowledge and data consultancy has shown to reduce significant health, social, and economic burdens amongst the field of Psychiatry. However, at this time there are was no published available data or general guidelines on optimal dosage, dosage frequency, or interval dosages for the administration of N-methyl-d-aspartate receptor antagonists other than that provided by anesthetic use in Emergency Room patients and induction. Global has paved the way to sustain TRD and MDD remission together with healthcare groups and key workers. We aim to work with others who specialise in this field and will assist or freely offer our guidance to those wishing to achieve the sustained remission of patients with MDD and TRD.Â
Company Information
Company Product
- Global NDMA therapy forGlobal NDMA therapy forGlobal NDMA therapy for